Insider Selling: Raptor Pharmaceutical Corp. Insider Unloads 25,000 Shares of Stock (RPTP)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) Insider Thomas Daley sold 25,000 shares of the stock on the open market in a transaction dated Monday, September 9th. The shares were sold at an average price of $14.28, for a total value of $357,000.00. Following the transaction, the insider now directly owns 69,906 shares in the company. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on RPTP. Analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $12.00 to $14.00 in a research note to investors on Friday, August 9th. Separately, analysts at JMP Securities raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $13.00 to $15.00 in a research note to investors on Friday, August 9th. Finally, analysts at Canaccord Genuity raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $14.00 to $16.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock.
One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Raptor Pharmaceutical Corp. currently has a consensus rating of “Buy” and a consensus price target of $12.17.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 1.03% during mid-day trading on Wednesday, hitting $14.69. 760,782 shares of the company’s stock traded hands. Raptor Pharmaceutical Corp. has a 1-year low of $4.35 and a 1-year high of $14.90. The stock has a 50-day moving average of $11.93 and a 200-day moving average of $8.23. The company’s market cap is $876.4 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). Analysts expect that Raptor Pharmaceutical Corp. will post $-1.23 EPS for the current fiscal year.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.